期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Seroprevalence of HIV, Hepatitis B and C Viruses Infections among Candidates for Cataract Surgery
1
作者 Angue Tatiana Harly Mba Aki emmanuel anyunzoghe +4 位作者 emmanuel anyunzoghe Patrice Emery Itoudi Bignoumba Stéphanie Ndjillekissa Ndjié Christian Agaya emmanuel Mve Mengome 《Open Journal of Ophthalmology》 2019年第2期47-53,共7页
Introduction: The safety issue of mass surgeries in areas of higher endemicity for HIV, HBV and HCV is raised. Objective: The objective was to determine the frequency of HIV, HBV and HCV among people undergoing a cata... Introduction: The safety issue of mass surgeries in areas of higher endemicity for HIV, HBV and HCV is raised. Objective: The objective was to determine the frequency of HIV, HBV and HCV among people undergoing a cataract surgery during humanitarian surgical mission. Patients and Method: This prospective study was conducted at CHU Owendo from April to September 2018. Cataract-operated patients were the targeted population. Rapid screening tests were used for diagnosis. Parameters such as age, sex, frequency of HIV, HBV, HCV, and co-infections were analyzed. Sero-positivity was correlated with age and sex. A total of 1403 patients were included. Statistical analysis was performed with EPI Info 7.2 (Chi2 uncorrected, Mann-Whitnney and Wilcoxon, p Results: Patients mean age was 66.3 ± 11.6 years;42.1% of them were male. With 18.0% of the study population, HIV-positive people had mean age of 78.4 ± 9.3 years, compared to 61.2 ± 10.1 years for sero-negative (p < 0.001). HIV prevalence was 4.6% (95% CI = [3.7 - 5.9]), HBV was 2.9% (95% CI = [2.1 - 3.9]), and HCV was 11.8% (95% CI = [10.2 - 13.6]). Co-infections occurred in 1.2% (95% CI = [0.8 - 1.9]) of patients undergoing surgery. Conclusion: This study showed high prevalence of HIV, HBV and HCV among patients undergoing cataract surgery with predominance for HCV. Viral co-infections prevalence was also significant. 展开更多
关键词 HIV HCV HBV SURGERY CATARACT Libreville
下载PDF
Contribution at the Study of Neuroprotective Properties of Neuroglobin during Severe Chronic Glaucoma
2
作者 Jean Fidèle Nnang Essone Tatiana Harly Mba Aki Angue +5 位作者 Mounir Belmalih Rosalie Nkiéma Ludmila Betty Eke Ndouo emmanuel anyunzoghe Nathan Ekegue Félix Ovono Abessolo 《World Journal of Neuroscience》 2020年第1期42-67,共26页
Introduction: The mechanisms of overexpression of neuroglobin in patients with severe glaucoma (CG+) remain hypothetical. Objective: To study the anti-apoptotic, anti-hypoxic and anti-oxidant properties of neuroglobin... Introduction: The mechanisms of overexpression of neuroglobin in patients with severe glaucoma (CG+) remain hypothetical. Objective: To study the anti-apoptotic, anti-hypoxic and anti-oxidant properties of neuroglobin in CG+. Population and Methods: The visual field, as well as plasma dosage of neuroglobin (CmNgb, ng/ml), hypoxia inductible factor-1alpha (CmHIF-1α, pg/ml), glutathione peroxidase (CmGpx, pg/ml), and cytochrome C oxidase (CmCyt C, pg/ml) were carried out in 45 CG+ and 45 controls (CG-). The chi-2 test compared the proportions, and Spearman’s test studied the correlations between quantitative variables (p Results: CmNgb was 4.1 in CG+, versus 2.3 in CG- (p = 1.52 × 10-5). CmGpx was 1144.7 in CG+, versus 752.8 in GC- (p = 0.0199). CmHIF-1α was 4.1 in CG+, versus 3.5 in CG- (p = 0.4530). CmCyt C was 2303.26 in CG+, versus 1750.44 in CG- (p = 0.0450). In CG+, there was a correlation between CmNgb and CmGpx (r = 0.417;p = 0.004), CmNgb and CmHIF-1α (r = 0.644;p = 1.8 × 10-6), and between CmHIF-1α and CmGpx (r = 0.447;p = 0.002), CmHIF-1α and CmCyt C (r = 0.371;p = 0.012). None correlation was found between CmNgb and CmCyt C (r = 0.126;p = 0.370), as well as CmGpx and CmCyt C (r = 0.102;p = 0.505). Conclusion: The variations of apoptosis, hypoxic, and oxidative stress biomarkers were found between CG+ and CG-, as well as their correlations, suggesting that neuroglobin overexpression is related to its anti-apoptotic, anti-oxidative, and anti-hypoxic properties. 展开更多
关键词 CHRONIC SEVERE GLAUCOMA NEUROGLOBIN Neuroprotective-Properties
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部